fluorescein-5-isothiocyanate has been researched along with docetaxel anhydrous in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anish, C; Bagchi, T; Jinturkar, KA; Kumar, MK; Misra, AR; Panda, AK | 1 |
| Kong, CC; Liu, XD; Song, CY; Tian, X | 1 |
2 other study(ies) available for fluorescein-5-isothiocyanate and docetaxel anhydrous
| Article | Year |
|---|---|
Liposomal formulations of Etoposide and Docetaxel for p53 mediated enhanced cytotoxicity in lung cancer cell lines.
Topics: Annexin A5; beta-Galactosidase; Cell Death; Cell Line, Tumor; Chemistry, Pharmaceutical; Coumarins; Deoxyribonucleases; Docetaxel; Electrophoresis, Agar Gel; Electrophoretic Mobility Shift Assay; Etoposide; Flow Cytometry; Fluorescein-5-isothiocyanate; Freeze Drying; Humans; Intracellular Space; Liposomes; Lung Neoplasms; Microscopy, Electron, Transmission; Particle Size; Static Electricity; Taxoids; Transfection; Tumor Suppressor Protein p53 | 2012 |
Bufalin Induces Programmed Necroptosis in Triple-Negative Breast Cancer Drug-Resistant Cell Lines through RIP1/ROS-Mediated Pathway.
Topics: Antioxidants; Apoptosis; Bufanolides; Caspase 3; Cell Line; Cell Line, Tumor; Cysteine; Docetaxel; Doxorubicin; Fluorescein-5-isothiocyanate; Humans; Necroptosis; Propidium; Reactive Oxygen Species; Receptors, Tumor Necrosis Factor; Triple Negative Breast Neoplasms; Tumor Necrosis Factor-alpha | 2022 |